STOCK TITAN
  1. Home
  2. News
  3. NVCR

NovoCure Ltd - NVCR STOCK NEWS

Welcome to our dedicated news page for NovoCure (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on NovoCure.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NovoCure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NovoCure's position in the market.

News
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Rhea-AI Summary
Novocure (NVCR) announced the results of the METIS phase 3 clinical trial for brain metastases from NSCLC will be presented at ASCO 2024. The trial showed a significant improvement in time to intracranial progression with TTFields therapy. The data will be presented by Minesh Mehta, MD, during ASCO's Central Nervous System Tumors session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
clinical trial
-
News
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Rhea-AI Summary
Novocure (NVCR) announces 20 presentations on Tumor Treating Fields therapy at AACR Annual Meeting 2024, highlighting enhanced therapeutic effects in pancreatic cancer, immunomodulatory role, and synergy with PARP inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
none
-
News
Novocure to Report First Quarter 2024 Financial Results
Rhea-AI Summary
Novocure (NVCR) will report financial results for Q1 2024 on May 2, 2024, before the U.S. markets open. A conference call and webcast will discuss the financial results at 8:00 a.m. EDT on the same day. Investors can access the call and webcast through provided links on Novocure's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences earnings
News
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Rhea-AI Summary
Zai Lab 's partner Novocure announces positive results from the phase 3 METIS clinical trial showing a significant improvement in time to intracranial progression for patients with brain metastases from non-small cell lung cancer treated with Tumor Treating Fields therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
clinical trial
-
News
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Rhea-AI Summary
Novocure (NVCR) announces positive results from the phase 3 METIS trial, showing a significant improvement in time to intracranial progression for patients with brain metastases from NSCLC treated with Tumor Treating Fields therapy. The trial demonstrated a median time to intracranial progression of 21.9 months compared to 11.3 months for patients receiving supportive care alone. TTFields therapy was well-tolerated, with sustained quality of life and neurocognitive function. Novocure plans to submit the data to regulatory authorities and publish them in a scientific journal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.01%
Tags
clinical trial
-
News
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
Rhea-AI Summary
Novocure (NVCR) announces positive results from an exploratory subgroup analysis of the INNOVATE-3 clinical trial, showing a significant improvement in overall survival for PLD-naïve patients treated with TTFields therapy and paclitaxel compared to those treated with paclitaxel alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
none
News
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Rhea-AI Summary
Novocure (NVCR) reports full year 2023 net revenues of $509 million, with fourth quarter net revenues of $134 million. The PMA application for TTFields in NSCLC is accepted by the FDA. Enrollment completed in phase 3 TRIDENT trial for newly diagnosed GBM. Novocure highlights achievements in commercial, clinical, and product development programs, aiming for sustained success in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
earnings
-
News
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Rhea-AI Summary
Novocure (NVCR) announced that the FDA has accepted its PMA application for the use of TTFields therapy in treating non-small cell lung cancer (NSCLC) after platinum-based therapy. The filing date was December 15, 2023, and the company expects a regulatory decision in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.75%
Tags
clinical trial
-
News
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Rhea-AI Summary
Novocure (NVCR) completes enrollment in TRIDENT trial, evaluating Optune Gio for newly diagnosed glioblastoma patients. Final data expected in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
clinical trial
News
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
Rhea-AI Summary
Novocure (NVCR) reports preliminary full year 2023 net revenues of $509 million, 4% increase in Q4 net revenues, and submission of PMA application for TTFields in NSCLC to FDA. The company also appointed a new Chief Medical Officer and will present at the 42nd Annual J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
earnings
Stock NVCR logo
NovoCure Ltd

Nasdaq:NVCR

NVCR Rankings

#2217 Ranked by Market Cap
#5351 Ranked by Stock Gains
N/A Ranked by Dividends

NVCR Stock Data

1.45B
95.92M
1.67%
85.87%
4.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Jersey
No 4 Grenville Street

About NVCR

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.